Table 1.
Patients’ characteristics
| Characteristic | Value | Standardized difference (%) / Sorror | Standardized difference (%) / Parimon1 |
|---|---|---|---|
| Median age (range), y | 31 (4 to 64) | 62 | |
| Age < 15 y, no. (%) | 57 (20) | ||
| Female patients, no. (%) | 117 (41) | 0 | |
| Diagnosis, no. (%) | |||
| AML | 86 (30) | 7 | |
| ALL | 57 (20) | 28 | |
| MM | 21 (7) | 4 | |
| Sickle cell disease and thalassemic syndromes | 16 (6) | * | |
| NHL | 16 (6) | 11 | |
| CML | 16 (6) | 43 | |
| MDS | 15 (5) | 44 | |
| HD | 14 (5) | 16 | |
| FA | 13 (4) | * | |
| Other malignancies | 13 (4) | 29 | |
| Other non malignancies | 19 (7) | *48 | |
| Disease risk | |||
| Low | 38 (13) | 28 | |
| Intermediate | 156 (55) | 57 | |
| High | 92 (32) | 25 | |
| Hematopoietic cell source, no. (%) | |||
| Marrow | 123 (43) | 29 | 71 |
| PBSC | 124 (43) | 59 | 43 |
| Cord blood | 20 (7) | *57 | *51 |
| Double cord blood | 19 (7) | * | * |
| Donor type, no. (%) | |||
| Matched related | 149 (52) | *6 | 10 |
| Matched unrelated | 63 (22) | 6 | 4 |
| Other | 74 (26) | * | 29 |
| Conditioning regimen, no. (%) | |||
| BU + CY | 92 (32) | 23 | *8 |
| CY + 12 Gy TBI | 64 (22) | 16 | 14 |
| 2 Gy TBI | 25 (9) | 11 | **93 |
| Fludarabine + 2 Gy TBI | 35 (12) | 27 | ** |
| Fludarabine + EDX or Mel ± SAL | 28 (10) | *82 | ** |
| Other myeloablative regimen | 11 (4) | * | * |
| Other non myeloablative regimen | 31 (11) | * | |
| GVHD prophylaxis, no. (%) | |||
| CSP + MTX | 150 (52) | 67 | |
| CSP + MMF | 100 (35) | 39 | |
| CSP + MP | 31 (11) | *52 | |
| CSP alone or MMF + MP | 4 (1) | * |
1
development group
* and **: grouped categories